- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
The leukotriene <scp>B<sub>4</sub></scp> receptors <scp>BLT1</scp> and <scp>BLT2</scp> as potential therapeutic targets
-
- Takehiko Yokomizo
- Department of Biochemistry, Graduate School of Medicine Juntendo University Tokyo Japan
-
- Takao Shimizu
- Institute of Microbial Chemistry Tokyo Japan
Search this article
Description
<jats:title>Summary</jats:title><jats:p>Leukotriene B<jats:sub>4</jats:sub> (LTB<jats:sub>4</jats:sub>) was recognized as an arachidonate‐derived chemotactic factor for inflammatory cells and an important drug target even before the molecular identification of its receptors. We cloned the high‐ and low‐affinity LTB<jats:sub>4</jats:sub> receptors, BLT1 and BLT2, respectively, and examined their functions by generating and studying gene‐targeted mice. BLT1 is involved in the pathogenesis of various inflammatory and immune diseases, including asthma, psoriasis, contact dermatitis, allergic conjunctivitis, age‐related macular degeneration, and immune complex‐mediated glomerulonephritis. Meanwhile, BLT2 is a high‐affinity receptor for 12‐hydroxyheptadecatrienoic acid, which is involved in the maintenance of dermal and intestinal barrier function, and the acceleration of skin and corneal wound healing. Thus, BLT1 antagonists and BLT2 agonists are promising candidates in the treatment of inflammatory diseases.</jats:p>
Journal
-
- Immunological Reviews
-
Immunological Reviews 317 (1), 30-41, 2023-03-13
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360861707159083904
-
- ISSN
- 1600065X
- 01052896
-
- Article Type
- journal article
-
- Data Source
-
- Crossref
- KAKEN
- OpenAIRE